Merck's drug K subcutaneous injection has been approved by the FDA for market launch.

Zhitong Financial APP learned that Merck (MRK.US) announced that Keytruda QLEX (subcutaneous injection Keytruda) has been approved by the US FDA for listing, used for all solid tumor indications that Keytruda intravenous version has previously been approved for. In June this year, the subcutaneous injection formulation of Keytruda has been filed for listing in China, and is expected to be approved domestically next year.